sil-OS-tah-zol 
Absorption: Slowly absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 95–98% bound to plasma proteins; one active metabolite is 97.4% bound, the other is 66% bound.
Metabolism/Excretion: Extensively metabolized by the liver, two metabolites have platelet aggregation inhibitory activity; metabolites are mostly excreted by the kidneys.
Half-life: Cilostazol and its active metabolites — 11–13 hr.
Contraindicated in:
Use Cautiously in:
CV: hypotension, left ventricular outflow obstruction, palpitations, tachycardia.
GI: diarrhea.
Neuro: headache, dizziness.
Drug-Drug:
Drug-Food:
Therapeutic Classification: antiplatelet agents
Pharmacologic Classification: platelet aggregation inhibitors
NDC Code*